Feugiat nulla facilisis at vero eros et curt accumsan et iusto odio dignissim qui blandit praesent luptatum zzril.
+ (123) 1800-453-1546
info@example.com

Related Posts

    Sorry, no posts matched your criteria.

Title Image

منتجاتنا

Home  /  منتجاتنا  /  Pharmaceuticals  /  TRACID Tranexamic Acid

TRACID Tranexamic Acid

 

Composition : Tablet : Each film-coated tablet contains Tranexamic Acid BP 500 mg.

Injection IV/ IM : Each 5ml ampoule contains Tranexamic Acid BP 500 mg.

Indication : Haemorrhage or risk of haemorrhage in increased fibrinolysis or fibrinogenolysis. Local fibrinolysis may occur in the following conditions: Prostatectomy and bladder surgery, Menorrhagia, Epistaxis, Conisation of the cervix , Management of dental extraction in patients with coagulopathies, Ulcerative colitis, Haematuria, Gastrointestinal haemorrhage, General fibrinolysis as in prostatic and pancreatic cancer; after thoracic and other major surgery; in obstetrical complications such as abruptio placentae and post-partum haemorrhage; in leukaemia and liver diseases and in connection with thrombolytic therapy with streptokinase. Also indicated for hereditary angioneurotic oedema

Dosage & Administration : 2 – 3 tablets of 500 mg (15 – 25 mg/Kg), or 5 – 10 ml by slow intravenous injection at a rate of 1mL/minute, two to three times daily.

Prostatectomy: 5 – 10 ml by slow intravenous injection every eight hours (the first injection being given during the operation) for the first three days after surgery; thereafter 1 – 1.5 g orally three to four times daily until macroscopic haematuria is no longer present.

Menorrhagia : 1 g (2 tablets) orally three times daily for up to four days. Maximum dose 4 g daily. Tracid® therapy is initiated when bleeding has become profuse.

Epistaxis : 1.5 g orally three times daily for four to ten days. Tracid® solution for injection may be applied topically to the nasal mucosa of patients suffering from epistaxis. This can be done by soaking a gauze strip in the solution, and then packing the nasal cavity.

Haematuria : 1 – 1.5 g orally 2 – 3 times daily until macroscopic haematuria is no longer present.

Conisation of the Cervix : 1.5 g orally 3 times a day for 12 to 14 days post-operatively.

Dental Surgery in Patients with Coagulopathies : Immediately before surgery, 10 mg per kg body-weight should be given intravenously. After surgery, 25 mg per kg body-weight are given orally three to four times daily for six to eight days.

General Fibrinolysis: 1.0 g (10 ml) by slow intravenous injection three to four times daily.

Hereditary Angioneurotic Oedema : 1 – 1.5 g orally two to three times daily as intermittent or continuous treatment depending on whether the patient has prodromal symptoms or not.

Category: